Please assess the completion status of the following clinical trial:

Trial Title: BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component~* Previous treatment with at least one anti-angiogenic agent~* Progressed within 6 months of study enrollment~* Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease~* Must have available tumor tissue for submission~* Subjects must also meet various laboratory parameters for inclusion~Exclusion Criteria:~* Subjects with any active autoimmune disease or a history of known autoimmune disease~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: nivolumab - 0.3 mg/kg (Type: EXPERIMENTAL): None
- Arm 2: nivolumab - 2.0 mg/kg (Type: EXPERIMENTAL): None
- Arm 3: nivolumab - 10.0 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).